Scars - Pipeline Insight, 2024

This “Scars- Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Scars pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Scars Understanding

Scars: Overview

If the injury damages the top layer of the skin, patient likely sees new skin when the wound heals. To repair damage that goes deeper than the first layer, body makes a tissue that’s thicker than skin. This thicker tissue often becomes a scar. New scars have a pink to reddish color. As a scar matures, it often turns lighter or darker than your skin. Most scars are flat, and the skin on top tends to look wrinkled. If body makes lots of extra tissue, a raised scar is seen. Sometimes, the body makes an excessive amount of extra tissue and a raised scar that is bigger than the original wound is seen. This type of raised scar is called a keloid. A sunken scar, is seen if something causes a lot of inflammation in skin, such as acne or chickenpox. This happens because the inflammation destroys collagen in the skin. This type of scar tends to appear when acne or chickenpox heals. With the right wound care, it’s possible to minimize scarring. Sometimes, it can prevent a scar from forming. When caring for a wound, it’s important to keep it clean. When cleaning a wound, use soap and water. Never use hydrogen peroxide, which can further damage the skin. It’s also important to get stitches when patients need them. This can help the skin to heal and lessen scarring. Scars come in many shapes and sizes. If patient have two or more scars, patient may notice that the two scars look very different. This happens because so much affects what a scar looks like, including the: Cause (accident, acne, burn, surgery, etc.), wound (size and how deeply the wound penetrated your skin), body part (where you wounded your skin), wound care (how you treated the wound). A scar forms when the body heals an injury. When a person injure the skin, a scar can form after the wound heals.

Scars- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Scars pipeline landscape is provided which includes the disease overview and Scars treatment guidelines. The assessment part of the report embraces, in depth Scars commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Scars collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Scars R&D. The therapies under

development are focused on novel approaches to treat/improve Scars.

Scars Emerging Drugs Chapters

This segment of the Scars report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Scars Emerging Drugs

Granexin Gel : First String ResearchGranexin gel is a topical formulation of aCT1 developed to address unmet clinical needs within the field of dermatology. FirstString’s dermatology program is currently focused on three main areas: medical countermeasures, cutaneous scarring, and thermal burns. Currently the product is in Phase 2/3 stage of development in reducing scar severity in surgical wounds following bilateral anchor incision breast surgery.

STP 705 : SirnaomicsSirnaomics' product candidate, STP705, is a siRNA (small interfering RNA) therapeutic that takes advantage of a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to directly knock down both TGF-ß1 and COX-2 gene expression. The product candidate has received multiple IND approvals from both the U.S. FDA and Chinese NMPA, including treatments of cholangiocarcinoma, nonmelanoma skin cancer, and hypertrophic scar. STP705 has also received Orphan Drug Designation for treatment of cholangiocarcinoma and primary sclerosing cholangitis. A Phase 2a study of STP705 for treatment of squamous cell skin cancer (isSCC) in adult patients demonstrated positive efficacy and safety results, with 76% of all patients (19/25) achieving complete histologically clearance and the two optimal dosing ranges achieving 90% histological clearance of tumor cell in the lesion. No significant or serious adverse events, including no significant cutaneous skin reactions, were reported in the study, and the company was able to define a clear therapeutic window in advance of later stage studies.

Scars: Therapeutic Assessment

This segment of the report provides insights about the different Scars drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Scars

There are approx. 10+ key companies which are developing the therapies for Scars. The companies which have their Scars drug candidates in the most advanced stage, i.e. phaseII/ III include, First String Research

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Scars pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Scars: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Scars therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Scars drugs.

Scars Report Insights

• Scars Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Scars Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Scars drugs?
• How many Scars drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Scars?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Scars therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Scars and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Sirnaomics
• Roche
• OliX Pharmaceuticals
• Bonti
• FirstString Research
• Cellastra
• Scarless Laboratories
• Hugel
• RXi Pharmaceuticals, Corp.
• Olix Pharmaceuticals, Inc.
• Lemonex
• Krystal Biotech, Inc.

Key Products

• STP 705
• OLX 101A
• Granexin Gel
• RG 6354
• BMT101
• OLX10010
• AIV001
• LEM-S401

This product will be delivered within 2 business days.